OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy
Simona Gössi, Ulrike Bacher, Claudia Haslebacher, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3527-3527
Open Access | Times Cited: 12
Simona Gössi, Ulrike Bacher, Claudia Haslebacher, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3527-3527
Open Access | Times Cited: 12
Showing 12 citing articles:
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
Valerie Wittibschlager, Ulrike Bacher, Katja Seipel, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5688-5688
Open Access | Times Cited: 36
Valerie Wittibschlager, Ulrike Bacher, Katja Seipel, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5688-5688
Open Access | Times Cited: 36
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
Dilara Akhoundova, Katja Seipel, Ulrike Bacher, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 28
Dilara Akhoundova, Katja Seipel, Ulrike Bacher, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 28
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
Gemma Reynolds, Victoria Hall, Benjamin W. Teh
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 28
Gemma Reynolds, Victoria Hall, Benjamin W. Teh
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 28
Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review
Silvia Martinelli, Domenico Pascucci, Patrizia Laurenti
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 22
Silvia Martinelli, Domenico Pascucci, Patrizia Laurenti
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 22
Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
Jing An, Jie Zhao, Ping Zou, et al.
Cancer Medicine (2024) Vol. 13, Iss. 12
Open Access | Times Cited: 5
Jing An, Jie Zhao, Ping Zou, et al.
Cancer Medicine (2024) Vol. 13, Iss. 12
Open Access | Times Cited: 5
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Tingting Zhang, Weiwei Tian, Shuang Wei, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Tingting Zhang, Weiwei Tian, Shuang Wei, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis
Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2
Bruno Fattizzo, Nicolò Rampi, Wilma Barcellini
Blood Reviews (2023) Vol. 60, pp. 101077-101077
Open Access | Times Cited: 5
Bruno Fattizzo, Nicolò Rampi, Wilma Barcellini
Blood Reviews (2023) Vol. 60, pp. 101077-101077
Open Access | Times Cited: 5
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
Evgenii Shumilov, Hristo Boyadzhiev, Paolo Mazzeo, et al.
HemaSphere (2023) Vol. 7, Iss. 12, pp. e984-e984
Open Access | Times Cited: 4
Evgenii Shumilov, Hristo Boyadzhiev, Paolo Mazzeo, et al.
HemaSphere (2023) Vol. 7, Iss. 12, pp. e984-e984
Open Access | Times Cited: 4
Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections
Eleftheria Kampouri, Gemma Reynolds, Benjamin W. Teh, et al.
Current Opinion in Infectious Diseases (2024)
Closed Access | Times Cited: 1
Eleftheria Kampouri, Gemma Reynolds, Benjamin W. Teh, et al.
Current Opinion in Infectious Diseases (2024)
Closed Access | Times Cited: 1
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study
Georgios Angelidakis, Roy F. Chemaly, Pranoti Sahasrabhojane, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 1070-1070
Open Access
Georgios Angelidakis, Roy F. Chemaly, Pranoti Sahasrabhojane, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 1070-1070
Open Access
